The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP)
pathway, collectively called here “anti-CGRP/rec mAbs”, have dramatically improved …

Calcitonin gene-related peptide (CGRP) is probably the most potent vasodilator in cerebral
circulation. Forty years after its discovery, the new CGRP-targeted therapy monoclonal …

Migraine headache results from activation of meningeal nociceptors, however, the
hypothalamus is activated many hours before the emergence of pain. How hypothalamic …

Background Although the involvement of calcitonin gene-related peptide (CGRP) in
migraines is well-established, its specific role in investigating the aura phase, which often …

Background Clinical trials and observational studies with anti-calcitonin gene-related
peptide antibodies poorly investigated their impact on migraine prodromal and …

During a 1-year compassionate use program, 156 patients with migraine self-administered a
monthly dose of erenumab 140 mg with a subcutaneous autoinjector. Main inclusion criteria …

Migraine is a highly prevalent neurovascular disorder afflicting more than 15% of the global
population. Nearly three times more females are afflicted by migraine in the 18–50 years …

Targeting CGRP-pathways has substantially expanded our options for treating individuals
with migraine. Although the efficacy of these drugs on migraine aura is yet to be fully …

Recently, monoclonal antibodies (mAbs) directed against calcitonin gene-related peptide
(CGRP)(Eptinezumab, Fremanezumab, and Galcanezumab) or its receptor (Erenumab) …

Background Clinical trials on anti-calcitonin gene-related peptide monoclonal antibodies
poorly investigated their impact on migraine accompanying symptoms. Objective To …